Accueil > Résultats de la recherche > Suite de la publication

Profiles of peripheral CD4 + T cells count during antiretroviral treatment in senegalese adults infected by hiv : impact of therapeutic associations

Infection with Human Immunodeficiency Virus (HIV) remains a major public health problem despite advances in diagnosis and antiretroviral treatment. We aim to assess the immune reconstitution in Senegalese adults living with HIV. At this end, we conducted a cross-sectional study on 82 HIV-positive subjects under highly active antiretroviral therapy (HAART) to evaluate the peripheral TCD4 profiles during treatment as well as sociodemographic characteristics. Women were the most representative gender group (67%). The median age was 42 years at the inclusion and HIV-1 was predominant serotype (90%). At the beginning of HAART, median CD4 count were 250 cells/?l; 44% of patients living with HIV (PLHIV) had presented the stages ??? and ?? as defined by WHO. During the follow-up of 20 PLHIV1, we found a significant increase of CD4 counts with Combivir + Efavirenz (363 to 444 cells/?l; p = 0.023) and the combination Combivir + Nevirapine (n = 11) (266 to 355 cells/?l (p = 0.021) and Tenolam + Efavirenz (n = 38) (258 and 465 cells/?l; p < 0.001). However, no significant difference in CD4 count was observed for PLHIV-1 under Tenolam + Nevirapine (250 to 358 cells/?l; p = 0.108).For the Combivir + Kaletra secondline treatment, median of CD4 count was 80% fold inPLHIV-2 and PLHIV-1+2 after 12 months of treatment. We also found a positive change in the median CD4 count except for PLHIV-1+2 under Kaletra + Tenolam. We did not find association between the CD4 count and the duration of treatment (rho = 0.201 and p = 0.359). Poor adherence to treatment was observed in 13% of cases. Our data have shown that CD4T cells counts is an important aspect of monitoring of HAART, suggesting that overall, the HIV-1 treatment lines used in national guideline improve live of patients through enhancement of immune reconstitution.

Auteur(s) : Sylla Niang M., Derwiche R., Mbengue B., Sylva A., Mbow M., Sarr Fall K., Ghomsi J.A., Faye B., Diouf N., Boye O., Dieye T.N. and Dieye A.
Pages : 1-6
Année de publication : 2017
Revue : Journal of Immunology, Infection and Inflammatory Diseases,
N° de volume : 2
Type : Article
Mise en ligne par : SYLLA Maguette Dème